TrialJAMA ophthalmology2020

Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.

David K Wallace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.